Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...

BBB National Programs’ National Advertising Division reviewed a challenge brought by Novo Nordisk Inc. regarding express and ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

As consumers taking medications like Ozempic cut back on eating out, about 70% are spending more on cooking at home, ...

June could provide an opportunity for investors according to Evercore ISI with the Fed expected to lower interest rates and ...

Eli Lilly, the global pharmaceutical giant, said the Therapeutic Goods Administration had approved the use of its Mounjaro ...

Telehealth platform Hims & Hers is set to acquire UK startup Zava to strengthen its international presence. Meanwhile, ...

A federal deadline ending the sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count on.

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...